CONCORD

Concord Drugs Share PriceConcord Drugs

₹35.94
0.62 (1.76%)
As on 06 December, 2023 | 15:40 BSE: 538965 NSE: CONCORDISIN: INE858L01010

Concord Drugs Performance

Day Range

  • Low
  • High
₹ 35.94

52 Week Range

  • Low
  • High
₹ 35.94
  • Open Price
  • Previous Close
  • Volume

Start SIP in Concord Drugs

Start SIP

Concord Drugs Share Price

  • Over 1 Month 9.04%
  • Over 3 Month -1.05%
  • Over 6 Month 30.69%
  • Over 1 Year 5.86%

Concord Drugs Key Statistics

Concord Drugs Investment Rating

  • Master Rating:
  • Concord Biotech Ltd has an operating revenue of Rs. 910.76 Cr. on a trailing 12-month basis. An annual revenue growth of 21% is outstanding, Pre-tax margin of 38% is great, ROE of 18% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 19% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 103 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Concord Drugs Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 791214141315
Operating Expenses Qtr Cr 671112131215
Operating Profit Qtr Cr 2111111
Depreciation Qtr Cr 0000100
Interest Qtr Cr 0000000
Tax Qtr Cr 0000000
Net Profit Qtr Cr 1000000
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 5159
Operating Expenses Annual Cr 4753
Operating Profit Annual in Cr 46
Depreciation Cr 22
Interest Annual Cr 22
Tax Annual Cr 01
Net Profit Annual Cr 12
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 21
Cash from Investing Activity Annual Cr -20
Cash from Financing Annual Activity Cr 02
Net Cash Flow Annual Cr 02
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 3228
Fixed Assets Annual Cr 1415
Total Non Current Assets Annual Cr 1532
Total Current Assets Annual Cr 4124
Total Assets Annual Cr 5756
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 3432
ROE Annual % 36
ROCE Annual % 812
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 810
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 891413
Operating Expenses Qtr Cr 681312
Operating Profit Qtr Cr 2111
Depreciation Qtr Cr 0010
Interest Qtr Cr 0000
Tax Qtr Cr 0000
Net Profit Qtr Cr 1000
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr
Operating Expenses Annual Cr
Operating Profit Annual in Cr
Depreciation Cr
Interest Annual Cr
Tax Annual Cr
Net Profit Annual Cr
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr
Cash from Investing Activity Annual Cr
Cash from Financing Annual Activity Cr
Net Cash Flow Annual Cr
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr
Fixed Assets Annual Cr
Total Non Current Assets Annual Cr
Total Current Assets Annual Cr
Total Assets Annual Cr
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs
ROE Annual %
ROCE Annual %
Total Debt to Total Equity Annual --
EBDIT Annual Margin %

Concord Drugs Technicals

EMA & SMA

Current Price
₹35.94
0.62 (1.76%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹34.51
  • 50 Day
  • ₹34.21
  • 100 Day
  • ₹33.44
  • 200 Day
  • ₹32.28
  • 20 Day
  • ₹34.31
  • 50 Day
  • ₹34.14
  • 100 Day
  • ₹33.78
  • 200 Day
  • ₹31.12

Concord Drugs Resistance and Support

PIVOT
₹35.28
Resistance
First Resistance 36.55
Second Resistance 37.77
Third Resistance 39.05
RSI 55.64
MFI 50.76
MACD Single Line 0.17
MACD 0.29
Support
First Resistance 34.05
Second Resistance 32.77
Third Resistance 31.55

Concord Drugs Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 21,614 1,252,747 57.96
Week 16,132 1,097,446 68.03
1 Month 14,032 1,030,243 73.42
6 Month 18,910 1,250,929 66.15

Concord Drugs Result Highlights

Concord Drugs Synopsis

NSE-Medical-Biomed/Biotech

Concord Biotech Ltd. is involved in the business activities of Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 853.17 Cr. and Equity Capital is Rs. 10.46 Cr. for the Year ended 31/03/2023. Concord Biotech Ltd. is a Public Limited Listed company incorporated on 23/11/1984 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is U24230GJ1984PLC007440 and registration number is 007440.
Market Cap 14,031
Sales 1,310
Shares in Float 5.86
No of funds 60
Yield
Book Value 10.97
U/D Vol ratio 1.7
LTDebt / Equity 3
Alpha 0.41
Beta 0.86

Concord Drugs

Owner NameSep-23
Promoters 44.08%
Mutual Funds 5.58%
Insurance Companies 2.26%
Foreign Portfolio Investors 7.3%
Individual Investors 6.78%
Others 34%

Concord Drugs Management

Name Designation
Mr. Sudhir Vaid Chairman & Managing Director
Mr. Ankur Vaid Joint Managing Director & CEO
Mr. Ravi Kapoor Non Executive Director
Mr. Rajiv Ambrish Agarwal Non Exe. & Nominee Director
Mr. Utpal Sheth Non Exe. & Nominee Director
Mr. Amit Varma Non Exe. & Nominee Director
Ms. Bharti Khanna Independent Director
Mr. Anil Katyal Independent Director
Mr. Amitabh Thakore Independent Director
Mr. Arvind Agarwal Independent Director
Mr. Jayaram Easwaran Independent Director
Mr. Mandayam Chakravarthy Sriraman Independent Director

Concord Drugs Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Concord Drugs Corporate Action

Date Purpose Remarks
2023-11-14 Quarterly Results
2023-08-14 Quarterly Results
2023-05-30 Audited Results
2023-02-14 Quarterly Results
2022-11-14 Quarterly Results

Concord Drugs FAQs

What is Share Price of Concord Drugs ?

Concord Drugs share price is ₹35 As on 06 December, 2023 | 15:26

What is the Market Cap of Concord Drugs ?

The Market Cap of Concord Drugs is ₹33.5 Cr As on 06 December, 2023 | 15:26

What is the P/E ratio of Concord Drugs ?

The P/E ratio of Concord Drugs is 21.8 As on 06 December, 2023 | 15:26

What is the PB ratio of Concord Drugs ?

The PB ratio of Concord Drugs is 1.1 As on 06 December, 2023 | 15:26

Q2FY23